MHRA (UK)Original article
Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/40
RegulatoryLevetiracetam Neuraxpharm granules for oral solution in sachetNegative
AI Analysis
Summary
Neuraxpharm UK Limited reported a Class 4 Medicines Defect Notification to the MHRA regarding discrepancies between the approved Patient Information Leaflet and reference product safety information for Levetiracetam granules.
Outcome Details
Class 4 Medicines Defect Notification: discrepancies identified between current product safety information and reference product information in Patient Information Leaflet
Importance:4/10
Sentiment:
-0.60
MHRAregulatory defectpatient safetyPIL discrepancylevetiracetamclass 4 notification
Read the original article
Published by MHRA (UK) on October 1, 2026 12:00 PM